Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Esophageal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 167 active trials
6 drugs · 136 active trials
6 drugs · 74 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 18 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Approved | Phase 3 | 24 | 15 | 5 | 62 | 1 | US | Sep 4, 2014 | 2014-10 |
| Nivolumab | Approved | Phase 3 | 23 | 12 | 9 | 37 | 4 | US | Dec 22, 2014 | Aug 17, 2015 |
| Tislelizumab | Approved | Phase 3 | 20 | 12 | 8 | 34 | 3 | US | Mar 13, 2024 | Jul 18, 2017 |
| Ipilimumab | Approved | Phase 3 | 4 | 2 | 1 | 8 | 1 | US | Mar 25, 2011 | Oct 12, 2016 |
| Zanidatamab | Approved | Phase 3 | 3 | 2 | 1 | 3 | 2 | US | Nov 20, 2024 | Dec 2, 2021 |
| Porfimer | Approved | Phase 2 | 0 | 0 | 0 | 1 | 2 | US | Dec 27, 1995 | 1995-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.